GUIDETTI, ANNA

GUIDETTI, ANNA  

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti  

Risultati 1 - 20 di 53 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autore(i) Tipo File Abstract
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 1-gen-2009 A. GuidettiC. Carlo-StellaA.M. Gianni + Article (author) -
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 1-gen-2004 C. Carlo-StellaA. GuidettiA.M. Gianni + Article (author) -
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 3-mag-2021 Castagna L.Corradini P.Guidetti A.De Philippis C. + Article (author) -
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival 1-mag-2018 Spina, FrancescoRADICE, TOMMASODe Philippis, ChiaraSOLDARINI, MARTINADi Chio, Maria ChiaraGuidetti, AnnaCorradini, Paolo + Article (author) -
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? 1-ott-2019 Guidetti, AnnaCorradini, Paolo + Article (author) -
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 15-ago-2004 C. Carlo-StellaA. GuidettiA. Gianni + Article (author) -
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 1-gen-2006 C. Carlo-StellaA. GuidettiC. LavazzaL. FarinaA.M. GianniP. Corradini + Article (author) -
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 25-apr-2022 Guidetti, AnnaBramanti, StefaniaMorello, LuciaDerenzini, EnricoCorradini, Paolo + Article (author) -
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 1-gen-2003 C. Carlo-StellaA. GuidettiA.M. Gianni + Article (author) -
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation : Life-threating Features Within the Early Post-engraftment Phase 1-ago-2020 Guidetti, AnnaCorradini, Paolo + Article (author) -
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP 1-gen-2021 Corradini, PaoloGuidetti, Anna + Article (author) -
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 14-ott-2021 Corradini P.Guidetti A. + Article (author) -
Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients 20-mar-2001 Guidetti A. + Article (author) -
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 1-gen-2012 C. Carlo-StellaA. GuidettiA.M. Gianni + Article (author) -
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 1-gen-2021 Guidetti, AnnaPennisi, MartinaFarina, LuciaCorradini, Paolo + Article (author) -
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 1-gen-2019 Guidetti, A.Barretta, F.Pellegrinelli, A.Pruneri, G.Pennisi, M.Di Chio, M. C.Facchetti, F.Corradini, P. + Article (author) -
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy : possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. 1-gen-2007 A. GuidettiA.M. Gianni + Article (author) -
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma 1-nov-2017 A. GuidettiE.V.M. Paterno'P. Corradini + Article (author) -
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 1-gen-2020 Taverna, FrancescaGuidetti, AnnaTarella, CorradoCorradini, PaoloRambaldi, Alessandro + Article (author) -
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 1-giu-2010 C. Carlo StellaA. GuidettiA. Gianni + Article (author) -